March 24, 2026 · /tirzepatide · 15 min read

Tirzepatide Dosage Chart: How Much to Take, How Often, and For How Long (2026)

Founder & Lead Researcher

Reviewed by Peptide Nerds Editorial · Updated April 2026

Important: We are not doctors. Everything in this article is based on published research and publicly available clinical data. It is not medical advice. Talk to your physician before changing any medication or health protocol.

Tirzepatide Dosage Chart: How Much to Take, How Often, and For How Long

The FDA-approved tirzepatide dosage starts at 2.5 mg once weekly, then increases every 4 weeks up to a maximum of 15 mg. In the SURMOUNT-1 trial, researchers administered 15 mg weekly for 72 weeks and observed an average weight loss of 20.9% (Jastreboff et al., 2022). But the dose that works best depends on tolerability, goals, and how your body responds. Here is what the clinical data actually shows at every dose level.

First time with tirzepatide? Our interactive protocol guide walks you through mixing, dosing, and the full titration schedule week by week.

The Bottom Line

Tirzepatide is the active ingredient in Mounjaro (for diabetes) and Zepbound (for weight loss). It is a prescription drug, not something you buy online.
You start at 2.5 mg once a week. That first dose is just to let your body adjust. It is not the treatment dose.
Your doctor increases the dose every 4 weeks. The full ramp-up takes about 5 months to reach the top dose of 15 mg.
In the biggest clinical trial, people on the highest dose lost about 21% of their body weight on average. Even the lowest treatment dose (5 mg) produced about 15% weight loss.
Side effects are mostly stomach-related (nausea, diarrhea) and hit hardest when the dose goes up. Going slow helps.
Your doctor decides the right dose for you. Not everyone needs the maximum. Talk to your physician before starting or changing anything.

Key Takeaways

The FDA-approved tirzepatide dosage range is 2.5 mg to 15 mg, administered once weekly by subcutaneous injection
Researchers observed the largest weight reductions at 15 mg, but 5 mg still produced 15% average weight loss at 72 weeks
The longest obesity trial (SURMOUNT-1) ran 72 weeks with a 20-week dose escalation period (Jastreboff et al., 2022)
GI side effects (nausea, diarrhea, vomiting) are dose-dependent and most common during titration
Tirzepatide is FDA-approved for both type 2 diabetes (Mounjaro) and chronic weight management (Zepbound)
Starting low and titrating every 4 weeks reduces GI side effects significantly compared to jumping straight to higher doses

What the Clinical Trials Used

Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates two incretin receptors instead of one. That dual action is what separates it from semaglutide, which only targets GLP-1.

The FDA-approved titration schedule follows the same pattern used in all major clinical trials. You start low. You increase slowly. The body adapts to each dose before moving up.

Tirzepatide Dosage Chart

Phase	Dose	Frequency	Duration	Source
Starting	2.5 mg	Once weekly	Weeks 1-4	SURMOUNT-1, PMID 35658024
Titration 1	5 mg	Once weekly	Weeks 5-8	SURMOUNT-1, PMID 35658024
Titration 2	7.5 mg	Once weekly	Weeks 9-12	SURMOUNT-1, PMID 35658024
Titration 3	10 mg	Once weekly	Weeks 13-16	SURMOUNT-1, PMID 35658024
Titration 4	12.5 mg	Once weekly	Weeks 17-20	SURMOUNT-1, PMID 35658024
Maintenance	15 mg	Once weekly	Weeks 21+	SURMOUNT-1, PMID 35658024

The 2.5 mg starting dose is not a treatment dose. It exists only to let the GI system adapt. The lowest effective dose studied in trials was 5 mg.

Not everyone needs to reach 15 mg. In SURMOUNT-1, separate groups were randomized to 5 mg, 10 mg, and 15 mg as their maximum doses. All three produced significant weight loss. Your physician determines the right maintenance dose based on your response and tolerability.

Why the Titration Matters

The slow ramp-up exists for a reason. GI side effects are the most common complaint with tirzepatide, and they hit hardest when the dose increases too fast.

In SURPASS-1, researchers found that nausea occurred in 12-18% of participants across dose groups, with most episodes happening during the titration phase (Rosenstock et al., 2021). Those numbers are manageable because the 4-week intervals give the body time to adjust before increasing.

Adverse events caused treatment discontinuation in 4.3% of participants at 5 mg, 7.1% at 10 mg, and 6.2% at 15 mg in SURMOUNT-1 (Jastreboff et al., 2022). Compare that to 2.6% for placebo. The dropout rate stays relatively low because the titration schedule works. Skipping steps or rushing the escalation increases the risk of severe nausea and vomiting.

Dose-Response: More Is Not Always Better

This is one of the most important sections in this guide. Higher doses produce more weight loss on average, but the gap between doses might surprise you.

Dose	Average Weight Loss	Participants Losing 20%+	Trial	Duration
5 mg	15.0%	35%	SURMOUNT-1	72 weeks
10 mg	19.5%	50%	SURMOUNT-1	72 weeks
15 mg	20.9%	57%	SURMOUNT-1	72 weeks
Placebo	3.1%	3%	SURMOUNT-1	72 weeks

Source: Jastreboff et al., 2022

Look at the jump from 5 mg to 10 mg: a 4.5 percentage point increase. Then from 10 mg to 15 mg: only 1.4 percentage points more. The law of diminishing returns applies. A person doing well on 10 mg may not gain much by pushing to 15 mg, but they will increase their exposure to side effects.

Many people do very well at moderate doses. 15% body weight loss at 5 mg is substantial. For a 250-pound person, that is roughly 37 pounds. Talk to your physician about whether a lower maintenance dose meets your goals before assuming you need to max out.

How Long to Take It

What the Studies Show

The SURMOUNT-1 trial ran for 72 weeks (roughly 17 months). That included a 20-week titration period and 52 weeks at the maintenance dose. Weight loss continued gradually throughout the trial, with most participants not reaching a true plateau until well past week 52 (Jastreboff et al., 2022).

SURMOUNT-4 extended the picture further. In that trial, participants first received tirzepatide for 36 weeks (open-label), achieving an average weight loss of 20.9%. Then they were randomized to either continue tirzepatide or switch to placebo for another 52 weeks (Aronne et al., 2024).

Those who continued tirzepatide reached an average total weight loss of 25.3% at 88 weeks. The drug kept working well past the initial trial period.

What Happens When You Stop

This is the question everyone asks. The SURMOUNT-4 data answers it clearly.

Participants who switched from tirzepatide to placebo at week 36 regained an average of 14% of their body weight over the next 52 weeks. By week 88, their net weight loss was 9.9%, compared to 25.3% for those who continued treatment (Aronne et al., 2024).

That is a significant regain. Only 16.6% of the placebo group maintained at least 80% of their initial weight loss, compared to 89.5% of the group that stayed on tirzepatide.

The takeaway is straightforward. Tirzepatide works as long as you take it. When you stop, the appetite suppression goes away, and most people gradually regain weight. This pattern is consistent with what researchers have observed with semaglutide and other GLP-1 agonists.

Ongoing treatment decisions should be made with your physician based on your individual response, risk factors, and goals.

Cycling Protocols

Tirzepatide is not a compound that benefits from cycling on and off. Unlike research peptides where receptor desensitization is a concern, GLP-1/GIP agonists are designed for continuous use under medical supervision.

The clinical data from SURMOUNT-4 makes the case clearly. Stopping and restarting leads to weight regain during the off period. There is no published evidence that "breaks" improve the long-term response to tirzepatide.

How to Administer

Tirzepatide (Mounjaro and Zepbound) comes in pre-filled, single-dose injection pens. There is no reconstitution required. No mixing. No math.

Injection Basics

Route: Subcutaneous injection (under the skin)
Sites: Abdomen, thigh, or upper arm. Rotate injection sites each week.
Day of week: Same day each week. Can be taken with or without food.
Storage: Refrigerate at 36-46 F (2-8 C). Can be kept at room temperature (up to 86 F / 30 C) for up to 21 days.

If You Miss a Dose

The FDA prescribing information states: if a dose is missed, administer it as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day.

Side Effects by Dose

GI side effects are the most common and they increase with dose. Here is what the clinical trials reported.

SURMOUNT-1 Side Effect Data (72 Weeks)

Side Effect	5 mg	10 mg	15 mg	Placebo	Source
Nausea	24.6%	33.3%	31.0%	9.5%	PMID 35658024
Diarrhea	18.7%	21.2%	23.0%	7.3%	PMID 35658024
Constipation	11.7%	11.5%	11.7%	5.8%	PMID 35658024
Vomiting	8.3%	10.7%	12.2%	1.7%	PMID 35658024
Discontinuation due to AEs	4.3%	7.1%	6.2%	2.6%	PMID 35658024

SURPASS-2 Side Effect Data (40 Weeks, Diabetes Population)

Side Effect	5 mg	10 mg	15 mg	Semaglutide 1 mg	Source
Nausea	17%	20%	22%	18%	PMID 34170647
Diarrhea	13%	16%	14%	12%	PMID 34170647
Vomiting	6%	8%	10%	8%	PMID 34170647

A few things stand out. Nausea rates are higher in the obesity population (SURMOUNT-1) than in the diabetes population (SURPASS-2). This may be related to higher doses, longer duration, or differences in baseline characteristics.

The good news: most GI side effects are mild to moderate and concentrated in the first few weeks after each dose increase. They typically improve as the body adjusts.

Managing Side Effects

These strategies come from clinical guidance and prescribing information:

Eat smaller meals. Large meals combined with delayed gastric emptying cause the worst nausea.
Avoid high-fat and fried foods during the first 2-3 weeks after each dose increase.
Stay hydrated. Diarrhea and vomiting increase dehydration risk.
Report persistent vomiting to your physician. If you cannot keep food or fluids down for more than 24 hours, that warrants medical attention.
Do not increase the dose if side effects have not resolved from the current dose. Talk to your physician about staying at the current level longer before titrating up.

How Tirzepatide Compares

Tirzepatide is not the only option in the GLP-1 class. Here is how it stacks up against the most commonly discussed alternatives.

Compound	Starting Dose	Max Dose	Frequency	Mechanism	Weight Loss (Max Dose)
Tirzepatide (Zepbound)	2.5 mg	15 mg	Weekly	GIP + GLP-1	20.9% at 72 wks
Semaglutide (Wegovy)	0.25 mg	2.4 mg	Weekly	GLP-1 only	14.9% at 68 wks
Retatrutide	1 mg	12 mg	Weekly	GIP + GLP-1 + Glucagon	24.2% at 48 wks

Sources: Tirzepatide (PMID 35658024); Semaglutide (Wilding et al., 2021, PMID 33567185); Retatrutide (Jastreboff et al., 2023, PMID 37366315)

Tirzepatide produced more weight loss than semaglutide in the head-to-head SURPASS-2 trial in type 2 diabetes patients. All three tirzepatide doses were superior to semaglutide 1 mg for both blood sugar control and weight reduction (Frias et al., 2021).

Retatrutide adds a glucagon receptor component that tirzepatide does not have. Early Phase 2 data shows higher weight loss numbers, but retatrutide is still investigational and not yet FDA-approved.

For the full comparison, see our tirzepatide vs semaglutide guide and our retatrutide dosage guide.

How to Get This Legally

FDA-Approved Options

Tirzepatide is FDA-approved under two brand names:

Mounjaro (for type 2 diabetes). Approved May 2022. Requires a type 2 diabetes diagnosis for on-label prescribing.
Zepbound (for chronic weight management). Approved November 2023. For adults with BMI 30+ or BMI 27+ with at least one weight-related condition.

Both are prescription-only. They require a physician to prescribe. Insurance coverage varies widely. Many commercial plans cover Mounjaro for diabetes. Coverage for Zepbound is more limited but expanding.

Telehealth Providers

Several telehealth platforms now prescribe tirzepatide for weight management. These typically include a virtual consultation, ongoing monitoring, and home delivery of the medication. Check that any provider you consider uses a licensed physician (not just a nurse practitioner in every state) and sources medication from FDA-approved manufacturers.

Compounding Pharmacies

As of March 2026, the FDA's position on compounded tirzepatide is evolving. Compounded versions existed during the drug shortage period. Check the FDA's current drug shortage list and consult your physician about whether branded or compounded tirzepatide is appropriate for your situation.

Frequently Asked Questions {#faq}

How much tirzepatide should I take for weight loss?

In the SURMOUNT-1 trial, researchers administered tirzepatide at 5 mg, 10 mg, and 15 mg once weekly. The 15 mg dose produced the greatest average weight loss at 20.9% over 72 weeks. However, 5 mg produced 15.0% weight loss, which is clinically meaningful for most people. The right dose depends on your individual response and tolerability. Talk to your physician about which maintenance dose makes sense for you.

How long does tirzepatide take to work?

Most participants in clinical trials began seeing measurable weight loss within the first 4-8 weeks. The rate of loss increased as the dose was titrated up. At 20 weeks (end of the titration period in SURMOUNT-1), participants had already lost a significant percentage of their starting weight. Weight loss continued for the full 72-week trial duration.

Can I take tirzepatide every day?

No. Tirzepatide is designed for once-weekly administration. The peptide has a half-life of approximately 5 days, which supports the weekly dosing schedule. All clinical trials used once-weekly injections. Taking it more frequently than prescribed increases the risk of side effects without evidence of improved results.

What happens if I miss a dose of tirzepatide?

Per the FDA prescribing information, if you miss a dose, take it as soon as possible within 4 days (96 hours). If more than 4 days have passed, skip the missed dose and take the next one on your regular day. Do not double up doses.

How do I know if my tirzepatide dose is too high?

Persistent nausea that does not improve after 2-3 weeks at a given dose, frequent vomiting, or inability to eat enough to maintain basic nutrition are signs the dose may be too high. If side effects from one dose level have not improved before your next scheduled increase, talk to your physician about staying at the current dose longer or stepping back down.

Is tirzepatide FDA-approved?

Yes. Tirzepatide is FDA-approved under two brand names. Mounjaro was approved in May 2022 for type 2 diabetes. Zepbound was approved in November 2023 for chronic weight management in adults with obesity or overweight with at least one weight-related condition.

Retatrutide Dosage Guide - the triple agonist with GLP-1, GIP, and glucagon activity
Fat Burning Peptides Explained - how GLP-1 agonists compare to direct lipolysis compounds
Semaglutide Compound Page - the GLP-1-only comparator
Weight Loss Goals: Research Guide - how peptides fit into the broader weight loss picture

Medical Disclaimer

The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any medication, including tirzepatide. Individual results vary. The editorial team shares published research findings, not medical recommendations. Tirzepatide is a prescription medication available only through a licensed physician. Talk to your physician about whether tirzepatide is appropriate for your situation.

References

Free Peptide Weight Loss Guide

Semaglutide vs. tirzepatide vs. retatrutide. Dosing protocols, side effects, gray market sourcing, and what the clinical trials found.